Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma

Published:2017-11-01 Issue:11 Volume:152 Page:1048
ISSN:2168-6254
Container-title:JAMA Surgery
language:en
Short-container-title:JAMA Surg

Author:

Cloyd Jordan M.¹,Wang Huamin²,Egger Michael E.¹,Tzeng Ching-Wei D.¹,Prakash Laura R.¹,Maitra Anirban²,Varadhachary Gauri R.³,Shroff Rachna³,Javle Milind³,Fogelman David³,Wolff Robert A.³,Overman Michael J.³,Koay Eugene J.⁴,Das Prajnan⁴,Herman Joseph M.⁴,Kim Michael P.¹,Vauthey Jean-Nicolas¹,Aloia Thomas A.¹,Fleming Jason B.¹,Lee Jeffrey E.¹,Katz Matthew H. G.¹

Affiliation:

1. Department of Surgical Oncology; University of Texas MD Anderson Cancer Center, Houston

2. Department of Pathology; University of Texas MD Anderson Cancer Center, Houston

3. Department of Gastrointestinal Medical Oncology; University of Texas MD Anderson Cancer Center, Houston

4. Department of Radiation Oncology; University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

Surgery

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuvant FOLFIRINOX;Journal of Clinical Medicine;2024-09-02

2. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer;Radiation Oncology;2024-08-19

3. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence;Surgery;2024-08

4. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy;JAMA Network Open;2024-06-18

5. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma;Minerva Surgery;2024-06